AL Amyloidosis with Oral Mucosal Bullous Lesions as Initial Symptom: A Case Report

doi:10.13701/j.cnki.kqyxyj.2025.10.013

Abstract

Abstract: Systemic light-chain (AL) amyloidosis is a malignant disorder associated with clonal plasma cell dyscrasia. It is characterized by the production of misfolded and unstable immunoglobulin light chains, leading to multisystem amyloid protein deposition, progressive organ dysfunction, and eventual failure. Oral mucosal bullous amyloidosis (OMBA) refers to a rare clinical manifestation of amyloidosis involving the skin and oral mucosa, presenting as bullous lesions. OMBA often initially manifests as dysphagia and is easily confused with other bullous mucosal diseases, resulting in misdiagnosis or missed diagnosis. This report presents a case of AL amyloidosis with OMBA as the primary clinical feature, diagnosed and managed at the Department of Oral and Maxillofacial Surgery, Henan Provincial People's Hospital. Combined with a review of the literature, the report discusses the clinical characteristics, diagnostic approaches, and treatment strategies of this rare condition. The aim is to enhance awareness of this disease among dental practitioners and reduce the incidence of misdiagnosis and missed diagnosis.

Key words: systemic light chain amyloidosis, oral mucosal bullous amyloidosis, diagnostic strategies

ZHANG Jingrui, MENG Xin, MA Jun, LI Xinyu, XU Ke, WANG Maiquan, LIN Dongpeng, WANG Yonggong. AL Amyloidosis with Oral Mucosal Bullous Lesions as Initial Symptom: A Case Report[J]. Journal of Oral Science Research, 2025, 41(10): 912-915.

References

[1] Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: A systematic review [J]. JAMA, 2020, 324(1): 79-89.
[2] Suranagi VV, Siddramappa B, Bannur HB, et al. Bullous variant of familial biphasic lichen amyloidosis: a unique combination of three rare presentations [J]. Indian J Dermatol, 2015, 60(1): 105.
[3] Maturana-Ramírez A, Ortega AV, Labbé FC, et al. Macroglossia, the first manifestation of systemic amyloidosis associated with multiple myeloma: Case report [J]. J Stomatol Oral Maxillofac Surg, 2018, 119(6): 514-517.
[4] Huang XH, Liu ZH. The clinical presentation and management of systemic light-chain amyloidosis in China [J]. Kidney Dis (Basel), 2016, 2(1): 1-9.
[5] Moreno V, Saba L, Tama-Shekan S, et al. Current and emerging immunotherapies for systemic AL amyloidosis [J]. Discov Med, 2024, 36(188): 1761-1771.
[6] Bou Zerdan M, Nasr L, Khalid F, et al. Systemic AL amyloidosis: current approach and future direction [J]. Oncotarget, 2023, 14: 384-394.
[7] Dispenzieri A, Buadi F, Kumar SK, et al. Treatment of immunoglobulin light chain amyloidosis: mayo stratification of myeloma and risk-adapted therapy (msmart) consensus statement [J]. Mayo Clin Proc, 2015, 90(8): 1054-1081.
[8] Ochiai T, Morishima T, Hao T, et al. Bullous amyloidosis: the mechanism of blister formation revealed by electron microscopy [J]. J Cutan Pathol, 2001, 28(8): 407-411.
[9] Johnson TM, Rapini RP, Hebert AA, et al. Bullous amyloidosis [J]. Cutis, 1989, 43(4): 346-352.
[10] Bieber T, Ruzicka T, Linke RP, et al. Hemorrhagic bullous amyloidosis. A histologic, immunocytochemical, and ultrastructural study of two patients [J]. Arch Dermatol, 1988, 124(11): 1683-1686.
[11] Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis [J]. Eur Heart J, 2017, 38(24): 1905-1908.
[12] Kimmich C, Schönland S, Kräker S, et al. Amyloid in bone marrow smears in systemic light-chain amyloidosis [J]. Amyloid, 2017, 24(1): 52-59.
[13] Mollee P, Renaut P, Gottlieb D, et al. How to diagnose amyloidosis [J]. Intern Med J, 2014, 44(1): 7-17.
[14] Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis [J]. N Engl J Med, 2007, 357(11): 1083-1093.
[15] Huang X, Ren G, Chen W, et al. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients [J]. Amyloid, 2021, 28(2): 75-83.
[16] Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach [J]. Haematologica, 2014, 99(4): 743-750.
[17] Kastritis E, Leleu X, Arnulf B, et al. A randomized phase Ⅲ trial of melphalan and dexamethasone (mdex) versus bortezomib, melphalan and dexamethasone (bmdex) for untreated patients with al amyloidosis [J]. Clin Lymphoma Myeloma, 2015, 15(S3): e59-e60.
[18] Gertz MA, Cohen AD, Comenzo RL, et al. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial [J]. Blood, 2023, 142(14): 1208-1218.
[19] Elad S, Czerninski R, Fischman S, et al. Exceptional oral manifestations of amyloid light chain protein (AL) systemic amyloidosis [J]. Amyloid, 2010, 17(1): 27-31.